Brief: Gubra Discontinues NYP2 Obesity Development with Boehringer Ingelheim

Gubra A/S

31/10/2024 10:10

Oct 31 (Reuters) - Gubra A/S  GUBRA.CO :
    * GUBRA ANNOUNCES DISCONTINUATION OF DEVELOPMENT OF NYP2 IN
OBESITY WITH BOEHRINGER INGELHEIM
    * OTHER THREE PROJECTS IN SUCCESSFUL PARTNERSHIP WITH
BOEHRINGER
REMAIN UNAFFECTED AND CONTINUE AS PLANNED
    * NO FURTHER INFORMATION HAS BEEN MADE AVAILABLE TO GUBRA

Source text:  ID:nMFN3cfJLB 
Further company coverage:  GUBRA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))